
NASDAQHealthcareMedical - Specialties
أحدث البيانات المتاحة
13.42 US$
+1.01 US$ · +8.14%
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
الإغلاق السابق
13.42 US$
+1.01 US$ · +8.14%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
نطاق اليوم
السعر الحالي 13.42 US$
نطاق 52 أسبوعًا
السعر الحالي 13.42 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
47
قيمة عادلة
المشاعر
55
مختلط
المخاطر
62
مخاطر مرتفعة
الزخم
43
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
نطاق اليوم
السعر الحالي 13.42 US$
نطاق 52 أسبوعًا
السعر الحالي 13.42 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 2.73 مليار USD | 2.78 مليار USD | 3 مليار USD | 3.27 مليار USD | 1.7 مليار USD |
| تكلفة البضاعة المباعة | 1.46 مليار USD | 1.5 مليار USD | 1.5 مليار USD | 1.33 مليار USD | 420.3 مليون USD |
| الربح الإجمالي | 1.27 مليار USD | 1.29 مليار USD | 1.5 مليار USD | 1.94 مليار USD | 1.28 مليار USD |
| البحث والتطوير | 186.2 مليون USD | 218.7 مليون USD | 246.8 مليون USD | 187.9 مليون USD | 95.7 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 746.3 مليون USD | 766.8 مليون USD | 763.2 مليون USD | 621 مليون USD | 239.6 مليون USD |
| نفقات التشغيل | 2.19 مليار USD | 3.25 مليار USD | 1.36 مليار USD | 1.09 مليار USD | 372.3 مليون USD |
| دخل الفوائد | — | — | 2.2 مليون USD | 1.3 مليون USD | 300 ألف USD |
| مصاريف الفوائد | 177.6 مليون USD | 188.3 مليون USD | 178.9 مليون USD | 74.5 مليون USD | 700 ألف USD |
| الاستهلاك والإطفاء | 442 مليون USD | 453.4 مليون USD | 457.2 مليون USD | 283.6 مليون USD | 52.7 مليون USD |
| الدخل التشغيلي | −919.2 مليون USD | −1.96 مليار USD | 139.1 مليون USD | 843.7 مليون USD | 906 مليون USD |
| صافي الدخل | −1.13 مليار USD | −2.05 مليار USD | −10.1 مليون USD | 548.7 مليون USD | 704.2 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
iShares Core S&P Small-Cap ETFIJR50.81 مليون0.05%103.19 مليار USD0.06%137.55 US$+0.17%
Avantis U.S. Small Cap Value ETFAVUV43.07 مليون0.14%30.85 مليار USD0.25%119.64 US$-0.41%
Vanguard Morningstar Total Stock Market ETFVTI31.35 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM22.78 مليون0.03%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Morningstar Small-Cap ETFVB22.62 مليون0.01%185.3 مليار USD0.03%289.48 US$+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR14.38 مليون0.02%68.2 مليار USD0.05%234.43 US$+0.22%
Vanguard Extended Market ETFVXF11.47 مليون0.01%95.4 مليار USD0.05%235 US$+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM7.84 مليون0.05%15.84 مليار USD0.03%53.45 US$+0.17%
iShares Core S&P Small-Cap ETFIJR
Avantis U.S. Small Cap Value ETFAVUV
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
Vanguard Extended Market ETFVXF
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSMالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.